Paradigm Asset Management’s TherapeuticsMD TXMD Stock Holding History

Paradigm Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-690	Closed	-$182K	–	511
2017 Q2	$182K	Sell	690 -712	-51%	-$178K	0.04%	355
2017 Q1	$505K	Buy	+1,402	New	+$434K	0.1%	268
2016 Q3	–	Sell	-255	Closed	-$108K	–	777
2016 Q2	$108K	Hold	255	–	–	0.02%	425
2016 Q1	$81.6K	Sell	255 -504	-66%	-$172K	0.02%	495
2015 Q4	$394K	Sell	759 -328	-30%	-$121K	0.07%	267
2015 Q3	$318K	Buy	+1,087	New	+$386K	0.04%	384
2014 Q4	–	Sell	-1,624	Closed	-$377K	–	826
2014 Q3	$377K	Sell	1,624 -970	-37%	-$244K	0.05%	359
2014 Q2	$573K	Buy	+2,594	New	+$577K	0.08%	286

Other funds holding TXMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Paradigm Asset Management's TXMD Position: Q3 2017 in Review

Paradigm Asset Management sold out of TherapeuticsMD (TXMD) in Q3 2017, closing a stake of 690 shares — an estimated $182K sold.

Paradigm Asset Management first reported a position in TXMD in Q2 2014 and held it in 8 quarters. The position peaked at $573K in Q2 2014. 134 funds tracked by Wall St. Rank hold TXMD as of Q3 2017.

Paradigm Asset Management reported no remaining TherapeuticsMD position as of Q3 2017 after selling out during the quarter.
Paradigm Asset Management sold 690 TherapeuticsMD shares in Q3 2017, an estimated $182K.
Paradigm Asset Management first reported a position in TherapeuticsMD in Q2 2014 and held it in 8 quarters.
Paradigm Asset Management's TherapeuticsMD position peaked at $573K in Q2 2014.
134 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2017.

Based on Paradigm Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.